| 1. Walsh DA, Franzyshen SK, Yanni JM.. (1989) Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds., 32 (1): [PMID:2562852] [10.1021/jm00121a022] |
| 2. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 3. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D.. (2003) Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches., 13 (10): [PMID:12729675] [10.1016/s0960-894x(03)00196-3] |
| 4. Pearlstein R, Vaz R, Rampe D.. (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior., 46 (11): [PMID:12747773] [10.1021/jm0205651] |
| 5. Zhang MQ, Wada Y, Sato F, Timmerman H.. (1995) (Piperidinylalkoxy)chromones: novel antihistamines with additional antagonistic activity against leukotriene D4., 38 (13): [PMID:7608912] [10.1021/jm00013a023] |
| 6. Carceller E, Merlos M, Giral M, Balsa D, Almansa C, Bartrolí J, García-Rafanell J, Forn J.. (1994) [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine., 37 (17): [PMID:7914928] [10.1021/jm00043a009] |
| 7. Keserü GM.. (2003) Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods., 13 (16): [PMID:12873512] [10.1016/s0960-894x(03)00492-x] |
| 8. Maynard GD, Bratton LD, Kane JM, Burkholder TP, Santiago B, Stewart KT, Kudlacz EM, Shatzer SA, Knippenberg RW, Farrell AM, Logan DE. (1997) Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity, 7 (22): [10.1016/S0960-894X(97)10097-X] |
| 9. Cavalli A, Poluzzi E, De Ponti F, Recanatini M.. (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers., 45 (18): [PMID:12190308] [10.1021/jm0208875] |
| 10. Zhang M, ter Laak AM, Timmerman H. (1991) Optical isomers of the H1 antihistamine terfenadine: synthesis and activity, 1 (8): [10.1016/S0960-894X(00)80261-9] |
| 11. Abou-Gharbia M, Moyer JA, Nielsen ST, Webb M, Patel U.. (1995) New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists., 38 (20): [PMID:7562938] [10.1021/jm00020a018] |
| 12. Menciu C, Duflos M, Fouchard F, Le Baut G, Emig P, Achterrath U, Szelenyi I, Nickel B, Schmidt J, Kutscher B, Günther E.. (1999) New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents., 42 (4): [PMID:10052971] [10.1021/jm981079+] |
| 13. Pagliara A, Testa B, Carrupt PA, Jolliet P, Morin C, Morin D, Urien S, Tillement JP, Rihoux JP.. (1998) Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist., 41 (6): [PMID:9526560] [10.1021/jm9704311] |
| 14. Zhang HC, Derian CK, McComsey DF, White KB, Ye H, Hecker LR, Li J, Addo MF, Croll D, Eckardt AJ, Smith CE, Li Q, Cheung WM, Conway BR, Emanuel S, Demarest KT, Andrade-Gordon P, Damiano BP, Maryanoff BE.. (2005) Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety., 48 (6): [PMID:15771419] [10.1021/jm049478u] |
| 15. Rajamani R, Tounge BA, Li J, Reynolds CH.. (2005) A two-state homology model of the hERG K+ channel: application to ligand binding., 15 (6): [PMID:15745831] [10.1016/j.bmcl.2005.01.008] |
| 16. Du LP, Tsai KC, Li MY, You QD, Xia L.. (2004) The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents., 14 (18): [PMID:15324906] [10.1016/j.bmcl.2004.06.070] |
| 17. Wang YH, Li Y, Li YH, Yang SL, Yang L.. (2005) Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism., 15 (18): [PMID:15990295] [10.1016/j.bmcl.2005.06.015] |
| 18. Cianchetta G, Singleton RW, Zhang M, Wildgoose M, Giesing D, Fravolini A, Cruciani G, Vaz RJ.. (2005) A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR., 48 (8): [PMID:15828831] [10.1021/jm0491851] |
| 19. Caron G, Ermondi G.. (2005) Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk)., 48 (9): [PMID:15857133] [10.1021/jm048980b] |
| 20. Tobita M, Nishikawa T, Nagashima R.. (2005) A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors., 15 (11): [PMID:15911273] [10.1016/j.bmcl.2005.03.080] |
| 21. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, Dansette PM, Mansuy D.. (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2., 16 (10): [PMID:16495056] [10.1016/j.bmcl.2006.02.004] |
| 22. Bondebjerg J, Fuglsang H, Valeur KR, Pedersen J, Naerum L.. (2006) Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors., 16 (13): [PMID:16647256] [10.1016/j.bmcl.2006.01.102] |
| 23. Zhu BY, Jia ZJ, Zhang P, Su T, Huang W, Goldman E, Tumas D, Kadambi V, Eddy P, Sinha U, Scarborough RM, Song Y.. (2006) Inhibitory effect of carboxylic acid group on hERG binding., 16 (21): [PMID:16931010] [10.1016/j.bmcl.2006.08.039] |
| 24. Bergström CA, Wassvik CM, Johansson K, Hubatsch I.. (2007) Poorly soluble marketed drugs display solvation limited solubility., 50 (23): [PMID:17929794] [10.1021/jm0706416] |
| 25. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E.. (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model., 51 (2): [PMID:18027916] [10.1021/jm070524a] |
| 26. Imai YN, Ryu S, Oiki S.. (2009) Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach., 52 (6): [PMID:19260734] [10.1021/jm801236n] |
| 27. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.. (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1., 51 (19): [PMID:18788725] [10.1021/jm8003152] |
| 28. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.. (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)., 51 (11): [PMID:18457386] [10.1021/jm7015683] |
| 29. Jia L, Sun H.. (2008) Support vector machines classification of hERG liabilities based on atom types., 16 (11): [PMID:18448342] [10.1016/j.bmc.2008.04.028] |
| 30. Zachariae U, Giordanetto F, Leach AG.. (2009) Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers., 52 (14): [PMID:19534531] [10.1021/jm900002x] |
| 31. Ermondi G, Visentin S, Caron G.. (2009) GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers., 44 (5): [PMID:19110341] [10.1016/j.ejmech.2008.11.009] |
| 32. Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, Zhang XS, McLeod RL, West RE, Williams SM, Hey JA.. (2009) Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs., 19 (17): [PMID:19660947] [10.1016/j.bmcl.2009.07.047] |
| 33. Lee PH, Conradi R, Shanmugasundaram V.. (2010) Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay., 20 (1): [PMID:19963379] [10.1016/j.bmcl.2009.11.039] |
| 34. Abu Khalaf R, Abu Sheikha G, Bustanji Y, Taha MO.. (2010) Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration., 45 (4): [PMID:20116902] [10.1016/j.ejmech.2009.12.070] |
| 35. Soulère L, Sabbah M, Fontaine F, Queneau Y, Doutheau A.. (2010) LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones., 20 (15): [PMID:20615699] [10.1016/j.bmcl.2010.06.081] |
| 36. Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068] |
| 37. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.. (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells., 2 (6): [PMID:16680159] [10.1038/nchembio790] |
| 38. Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.. (2009) Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum., 5 (10): [PMID:19734910] [10.1038/nchembio.215] |
| 39. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.. (2007) Chemical genetics reveals a complex functional ground state of neural stem cells., 3 (5): [PMID:17417631] [10.1038/nchembio873] |
| 40. PubChem BioAssay data set, |
| 41. PubChem BioAssay data set, |
| 42. PubChem BioAssay data set, |
| 43. PubChem BioAssay data set, |
| 44. PubChem BioAssay data set, |
| 45. PubChem BioAssay data set, |
| 46. Sinha N, Sen S.. (2011) Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model., 46 (2): [PMID:21185626] [10.1016/j.ejmech.2010.11.042] |
| 47. Wlodarczyk N, Le Broc-Ryckewaert D, Gilleron P, Lemoine A, Farce A, Chavatte P, Dubois J, Pommery N, Hénichart JP, Furman C, Millet R.. (2011) Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer., 54 (5): [PMID:21299244] [10.1021/jm101067y] |
| 48. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 49. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 50. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 51. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 52. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 53. PubChem BioAssay data set, |
| 54. Tukey RH, Strassburg CP.. (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease., 40 (1): [PMID:10836148] [10.1146/annurev.pharmtox.40.1.581] |
| 55. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.. (2001) Rational use of in vitro P-glycoprotein assays in drug discovery., 299 (2): [PMID:11602674] |
| 56. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 57. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 58. Mihalic JT, Fan P, Chen X, Chen X, Fu Y, Motani A, Liang L, Lindstrom M, Tang L, Chen JL, Jaen J, Dai K, Li L.. (2012) Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition., 22 (11): [PMID:22542010] [10.1016/j.bmcl.2012.04.006] |
| 59. Dang Z, Qian K, Ho P, Zhu L, Lee KH, Huang L, Chen CH.. (2012) Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants., 22 (16): [PMID:22818973] [10.1016/j.bmcl.2012.06.080] |
| 60. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein., 16 (1): [PMID:10213372] [10.1023/a:1018877803319] |
| 61. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 62. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M.. (1993) Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells., 45 (1): [PMID:8094615] [10.1016/0006-2952(93)90076-9] |
| 63. Wang EJ, Casciano CN, Clement RP, Johnson WW.. (2001) Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors., 289 (1): [PMID:11716514] [10.1006/bbrc.2001.6000] |
| 64. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 65. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.. (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions., 55 (10): [PMID:22541068] [10.1021/jm300212s] |
| 66. Hitchcock SA.. (2012) Structural modifications that alter the P-glycoprotein efflux properties of compounds., 55 (11): [PMID:22506484] [10.1021/jm201136z] |
| 67. Gemma S, Camodeca C, Sanna Coccone S, Joshi BP, Bernetti M, Moretti V, Brogi S, Bonache de Marcos MC, Savini L, Taramelli D, Basilico N, Parapini S, Rottmann M, Brun R, Lamponi S, Caccia S, Guiso G, Summers RL, Martin RE, Saponara S, Gorelli B, Novellino E, Campiani G, Butini S.. (2012) Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling., 55 (15): [PMID:22783984] [10.1021/jm300802s] |
| 68. PubChem BioAssay data set, |
| 69. PubChem BioAssay data set, |
| 70. Brudeli B, Moltzau LR, Nguyen CH, Andressen KW, Nilsen NO, Levy FO, Klaveness J.. (2013) Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist., 64 [PMID:23711770] [10.1016/j.ejmech.2013.03.060] |
| 71. Wang XF, Wang SB, Ohkoshi E, Wang LT, Hamel E, Qian K, Morris-Natschke SL, Lee KH, Xie L.. (2013) N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin., 67 [PMID:23867604] [10.1016/j.ejmech.2013.06.041] |
| 72. Settimo L, Bellman K, Knegtel RM.. (2013) Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds., [PMID:24249037] [10.1007/s11095-013-1232-z] |
| 73. Settimo L, Bellman K, Knegtel RM.. (2013) Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds., [PMID:24249037] [10.1007/s11095-013-1232-z] |
| 74. Wang XF, Guan F, Ohkoshi E, Guo W, Wang L, Zhu DQ, Wang SB, Wang LT, Hamel E, Yang D, Li L, Qian K, Morris-Natschke SL, Yuan S, Lee KH, Xie L.. (2014) Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site., 57 (4): [PMID:24502232] [10.1021/jm4016526] |
| 75. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 76. PubChem BioAssay data set, |
| 77. Mahesh Kumar P, Siva Kumar K, Meda CLT, Rajeshwar Reddy G, Mohakhud PK, Mukkanti K, Rama Krishna G, Malla Reddy C, Rambabu D, Shiva Kumar K, Krishna Priya K, Chennubhotla KS, Banote RK, Kulkarni P, Parsa KVL, Pal M. (2012) (Pd/C-mediated)couplingiodocyclizationcoupling strategy in discovery of novel PDE4 inhibitors: a new synthesis of pyrazolopyrimidines, 3 (6): [10.1039/C2MD00273F] |
| 78. Onwuha-Ekpete L, Tack L, Knapinska A, Smith L, Kaushik G, Lavoi T, Giulianotti M, Houghten RA, Fields GB, Minond D.. (2014) Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis., 57 (4): [PMID:24471466] [10.1021/jm4019542] |
| 79. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 80. Perlmutter JI, Forbes LT, Krysan DJ, Ebsworth-Mojica K, Colquhoun JM, Wang JL, Dunman PM, Flaherty DP.. (2014) Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus., 57 (20): [PMID:25238555] [10.1021/jm5010682] |
| 81. Medapi B, Renuka J, Saxena S, Sridevi JP, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D.. (2015) Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors., 23 (9): [PMID:25801151] [10.1016/j.bmc.2015.03.004] |
| 82. Rankovic Z.. (2015) CNS drug design: balancing physicochemical properties for optimal brain exposure., 58 (6): [PMID:25494650] [10.1021/jm501535r] |
| 83. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.. (2011) Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk., 91 [PMID:21300721] [10.1093/cvr/cvr044] |
| 84. Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.. (2012) Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment., 32 [PMID:22761000] [10.1002/jat.2784] |
| 85. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.. (2013) MICE models: superior to the HERG model in predicting Torsade de Pointes., 3 [PMID:23812503] [10.1038/srep02100] |
| 86. FDA drug approval package for Aliskiren hemifumarate, |
| 87. Loi CM, Smith DA, Dalvie D.. (2013) Which metabolites circulate?, 41 (5): [PMID:23454828] [10.1124/dmd.112.050278] |
| 88. Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.. (2012) Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity., 40 (5): [PMID:22328583] [10.1124/dmd.111.043505] |
| 89. Unpublished dataset, |
| 90. Unzue A, Lafleur K, Zhao H, Zhou T, Dong J, Kolb P, Liebl J, Zahler S, Caflisch A, Nevado C.. (2016) Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation., 112 [PMID:26907157] [10.1016/j.ejmech.2016.01.057] |
| 91. Hansen SV, Christiansen E, Urban C, Hudson BD, Stocker CJ, Due-Hansen ME, Wargent ET, Shimpukade B, Almeida R, Ejsing CS, Cawthorne MA, Kassack MU, Milligan G, Ulven T.. (2016) Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy., 59 (6): [PMID:26928019] [10.1021/acs.jmedchem.5b01962] |
| 92. Gurrapu S, Jonnalagadda SK, Alam MA, Ronayne CT, Nelson GL, Solano LN, Lueth EA, Drewes LR, Mereddy VR.. (2016) Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents., 26 (14): [PMID:27241692] [10.1016/j.bmcl.2016.05.054] |
| 93. WHO Anatomical Therapeutic Chemical Classification, |
| 94. British National Formulary (72nd edition), |
| 95. DrugMatrix, [10.6019/CHEMBL3885881] |
| 96. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
| 97. Lara-Ramirez EE, López-Cedillo JC, Nogueda-Torres B, Kashif M, Garcia-Perez C, Bocanegra-Garcia V, Agusti R, Uhrig ML, Rivera G.. (2017) An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method., 132 [PMID:28364659] [10.1016/j.ejmech.2017.03.063] |
| 98. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 99. Kang D, Fang Z, Huang B, Lu X, Zhang H, Xu H, Huo Z, Zhou Z, Yu Z, Meng Q, Wu G, Ding X, Tian Y, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.. (2017) Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants., 60 (10): [PMID:28481112] [10.1021/acs.jmedchem.7b00332] |
| 100. Elsebaei MM, Mohammad H, Abouf M, Abutaleb NS, Hegazy YA, Ghiaty A, Chen L, Zhang J, Malwal SR, Oldfield E, Seleem MN, Mayhoub AS.. (2018) Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)., 148 [PMID:29459278] [10.1016/j.ejmech.2018.02.031] |
| 101. HESI Myocyte Subteam: Blinova K., Brock M., Dang Q., Entcheva E., Feaster T.K., Gintant G., Guo, L., Herron T., Kanda Y., Kettenhofen R., Kraushaar U., Lu H.R., Lu J., Millard D., Objero-Paz C., Osada T., Pang L., Pierson J., Sawada K., Sekino Y., Shi H., Smith G., Snodgrass R., Stockbridge N., Strauss D.G., Traebert M., Wakatsuki T., Wu J., Zeng H., Zhang X.. (2019) Evaluation of the utility of stem-cell derived cardiomyocytes for drug proarrhythmic potential, [10.6019/CHEMBL4295262] |
| 102. Unpublished dataset, |
| 103. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 104. Cinelli MA, Reidl CT, Li H, Chreifi G, Poulos TL, Silverman RB.. (2020) First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate., 63 (9): [PMID:32302123] [10.1021/acs.jmedchem.9b01573] |
| 105. Kang D, Zhang H, Wang Z, Zhao T, Ginex T, Luque FJ, Yang Y, Wu G, Feng D, Wei F, Zhang J, De Clercq E, Pannecouque C, Chen CH, Lee KH, Murugan NA, Steitz TA, Zhan P, Liu X.. (2019) Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties., 62 (3): [PMID:30624934] [10.1021/acs.jmedchem.8b01656] |
| 106. Adebesin AM, Wesser T, Vijaykumar J, Konkel A, Paudyal MP, Lossie J, Zhu C, Westphal C, Puli N, Fischer R, Schunck WH, Falck JR.. (2019) Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogues as Potential Clinical Antiarrhythmic Agents., 62 (22): [PMID:31693857] [10.1021/acs.jmedchem.9b00952] |
| 107. Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado JC, Maher SP, Calla J, Plouffe D, Zhong Y, Chen K, Chaumeau V, Conway AJ, McNamara CW, Ibanez M, Gagaring K, Serrano FN, Eribez K, Taggard CM, Cheung AL, Lincoln C, Ambachew B, Rouillier M, Siegel D, Nosten F, Kyle DE, Gamo FJ, Zhou Y, Llinás M, Fidock DA, Wirth DF, Burrows J, Campo B, Winzeler EA.. (2018) Open-source discovery of chemical leads for next-generation chemoprotective antimalarials., 362 (6419): [PMID:30523084] [10.1126/science.aat9446] |
| 108. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 109. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 110. Corpas-López V, Tabraue-Chávez M, Sixto-López Y, Panadero-Fajardo S, Alves de Lima Franco F, Domínguez-Seglar JF, Morillas-Márquez F, Franco-Montalbán F, Díaz-Gavilán M, Correa-Basurto J, López-Viota J, López-Viota M, Pérez Del Palacio J, de la Cruz M, de Pedro N, Martín-Sánchez J, Gómez-Vidal JA.. (2020) O-Alkyl Hydroxamates Display Potent and Selective Antileishmanial Activity., 63 (11): [PMID:32392053] [10.1021/acs.jmedchem.9b02016] |
| 111. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 112. Shahin IG,Abutaleb NS,Alhashimi M,Kassab AE,Mohamed KO,Taher AT,Seleem MN,Mayhoub AS. (2020) Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections., 202 [PMID:32707373] [10.1016/j.ejmech.2020.112497] |
| 113. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 114. Abdel-Halim M, Sigler S, Racheed NAS, Hefnawy A, Fathalla RK, Hammam MA, Maher A, Maxuitenko Y, Keeton AB, Hartmann RW, Engel M, Piazza GA, Abadi AH.. (2021) From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity., 64 (8.0): [PMID:33793216] [10.1021/acs.jmedchem.0c01120] |
| 115. Fallica AN, Sorrenti V, D'Amico AG, Salerno L, Romeo G, Intagliata S, Consoli V, Floresta G, Rescifina A, D'Agata V, Vanella L, Pittalà V.. (2021) Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent In Vitro Antiproliferative Activity., 64 (18.0): [PMID:34472337] [10.1021/acs.jmedchem.1c00633] |
| 116. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
| 117. Institute for Molecular Medicine Finland - High Throughput Biomedicine Unit. (2023) ECBD screening data for assay EOS300108, [10.6019/EOS300108] |
